David McDonnell: Time for NLP to be part of mainstream GP consultation teaching?

Por McDonnell, David
Publicado em 2014

Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study

Por McDonnell, David P., Landry, John, Detke, Holland C.
Publicado em 2014

Eosinophilic myocarditis as a first presentation of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

Por Bluett, Ronan, McDonnell, David, O’Dowling, Claire, Vaughan, Carl
Publicado no BMJ Case Rep (2017)

Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment

Por Detke, Holland C., Lauriello, John, Landry, John, McDonnell, David P.
Publicado no Int J Methods Psychiatr Res (2014)

S226. A STUDY COMPARING WEIGHT GAIN FROM ALKS 3831 TO OLANZAPINE IN EARLY-ILLNESS YOUNG ADULTS WITH SCHIZOPHRENIFORM, SCHIZOPHRENIA, OR BIPOLAR I DISORDER

Por Simmons, Adam, McDonnell, David, Jiang, Ying, Graham, Christine, Silverman, Bernard
Publicado no Schizophr Bull (2018)

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendat...

Por Anand, Ernie, Berggren, Lovisa, Deix, Claudia, Tóth, Ágoston, McDonnell, David P
Publicado no Neuropsychiatr Dis Treat (2015)

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection

Por Atkins, Susan, Detke, Holland C, McDonnell, David P, Case, Michael G, Wang, Shufang
Publicado em 2014

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia

Por Hill, Angela L, Sun, Bin, Karagianis, Jamie L, Watson, Susan B, McDonnell, David P
Publicado em 2011

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, explorator...

Por Ascher-Svanum, Haya, Montgomery, William S, McDonnell, David P, Coleman, Kristina A, Feldman, Peter D
Publicado em 2012

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study

Por Ascher-Svanum, Haya, Novick, Diego, Haro, Josep Maria, Bertsch, Jordan, McDonnell, David, Detke, Holland
Publicado em 2013

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection

Por Ascher-Svanum, Haya, Novick, Diego, Haro, Josep Maria, Bertsch, Jordan, McDonnell, David, Detke, Holland
Publicado em 2014

F232. A PHASE 3 STUDY TO DETERMINE THE ANTIPSYCHOTIC EFFICACY AND SAFETY OF ALKS 3831 IN ADULT PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA

Por McDonnell, David, Potkin, Steven G, Simmons, Adam, Jiang, Ying, DiPetrillo, Lauren, Silverman, Bernard
Publicado no Schizophr Bull (2018)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases

Por Detke, Holland C, McDonnell, David P, Brunner, Elizabeth, Zhao, Fangyi, Sorsaburu, Sebastian, Stefaniak, Victoria J, Corya, Sara A
Publicado em 2010

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study

Por Katagiri, Hideaki, Tohen, Mauricio, McDonnell, David P, Fujikoshi, Shinji, Case, Michael, Kanba, Shigenobu, Takahashi, Michihiro, Gomez, Juan-Carlos
Publicado em 2013

Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective...

Por Jones, Meghan E., Andrews, Jeffrey S., Faries, Douglas E., Landry, John, Xu, Jenny, Detke, Holland C., Chhabra-Khanna, Rashna, McDonnell, David P.
Publicado no BMC Psychiatry (2015)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

Por McDonnell, David P, Detke, Holland C, Bergstrom, Richard F, Kothare, Prajakti, Johnson, Jason, Stickelmeyer, Mary, Sanchez-Felix, Manuel V, Sorsaburu, Sebastian, Mitchell, Malcolm I
Publicado em 2010

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

Por Stauffer Virginia L, Lawson Anthony H, Nyhuis Allen W, Detke Holland C, Zhao Fangyi, Ascher-Svanum Haya, Montgomery William, Witte Michael M, McDonnell David P
Publicado em 2011-09-01

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia

Por Ascher-Svanum, Haya, Zhao, Fangyi, Detke, Holland C, Nyhuis, Allen W, Lawson, Anthony H, Stauffer, Virginia L, Montgomery, William, Witte, Michael M, McDonnell, David P
Publicado em 2011